Related coverage linked through entity extraction aliases.
Jun 26, 2026
Studies reveal age-related infectious disease patterns including higher symptomatic rhinovirus risk in adults over 60, polypharmacy complications in infectious disease patients, and significant underutilization of COVID-19 antivirals among older adults despite proven benefits.
Jun 25, 2026
Otsuka's ADHD drug centanafadine met the primary endpoint in a Phase 3b trial in adults with comorbid anxiety, with results supporting its efficacy ahead of a July 24, 2026 FDA decision. The FDA has granted priority review to the New Drug Application for the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). If approved, centanafadine would be a novel treatment option for ADHD in children, adolescents, and adults.
Jun 20, 2026
The FDA reversed its initial rejection of Moderna's mRNA flu vaccine, agreeing to a normal review after public backlash, while a federal judge invalidated the ACIP advisory committee, leaving the US without functioning vaccine oversight. Moderna's vaccine showed 26.6% greater efficacy than standard flu shots in clinical trials.
Jun 19, 2026
An FDA advisory panel unanimously recommended approval of Moderna's mRNA flu vaccine mFlusiva for adults 50 and older. The vaccine showed a 27% reduction in flu cases versus a standard shot. A final FDA decision is expected by early August.
Jun 16, 2026
Acurx Pharmaceuticals is advancing ibezapolstat to international Phase 3 clinical trials for C. difficile infection following final regulatory guidance from FDA and EMA. The company launched a new clinical trial program for recurrent CDI and presented structural biology research demonstrating ibezapolstat's mechanism of action. Acurx reported year-end 2025 cash of $7.6 million.
Jun 10, 2026
Twenty years after HPV vaccine approval, head and neck cancers have become the most common HPV-related cancer with 16,000 cases annually. The incidence tripled from 2000 to 2017, primarily affecting men in their 40s to 60s. Vaccination rates among teens reached approximately 77-79% for at least one dose in 2024.
Jun 06, 2026
Clover Hill Dairy recalled requesón/soft ricotta cheese on June 3, 2026, over potential Listeria contamination, with products sold in New York and Virginia. Listeria causes approximately 1,250 U.S. cases annually with an 86% hospitalization rate, and poses severe risks to pregnant women including pregnancy loss and stillbirth. Health officials advise pregnant individuals to avoid raw milk products, soft cheeses, deli meats, and hot dogs.
Jun 05, 2026
The US is intensifying its response to New World screwworm as confirmed cases approach within 62 miles of the US-Mexico border. Emergency exemptions allow import of new treatments from Brazil, while sterile fly releases are expanded and a $100 million research initiative is launched. All southern ports of entry remain closed to livestock trade.
May 30, 2026
Two experimental ALS therapies showed promise in recent clinical developments. Interim Phase 1/2 data suggest the antisense oligonucleotide QRL-201 restores a critical nerve protein and may slow disease decline, with a Phase 3 trial planned for 2027. Meanwhile, the oral therapy neflamapimod has been selected for testing in the UK's EXPERTS-ALS platform study, with first results expected this spring.
May 28, 2026
Immunic presented new Phase 2 CALLIPER data at CMSC 2026 showing vidofludimus calcium's favorable effects in progressive MS, including a novel unified disability endpoint. The company also secured $400M in private placement to fund Phase 3 ENSURE studies and commercial preparations.
May 13, 2026
The FDA reversed its refusal to review Moderna’s mRNA flu vaccine application and accepted a revised filing with split age cohorts and a post-market study for adults over 65. The reversal came amid broader vaccine regulatory uncertainty and industry concern about unpredictable review timelines.
Apr 26, 2026
Congress rejected the administration’s deepest proposed science cuts, increasing NIH funding by about $415 million to $48.7 billion. NASA and NSF also saw far smaller reductions than proposed.
Apr 23, 2026
The acting director of the CDC delayed publication of a report showing the COVID-19 vaccine cut emergency department visits and hospitalizations for healthy adults last winter by about half. The Department of Health and Human Services did not immediately respond to request for comment.
Apr 21, 2026
VYLOY (zolbetuximab-clzb) remains the only approved CLDN18.2-targeted therapy for first-line HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors. The pipeline is focused on next-generation antibodies, ADCs, CAR-T, NK-cell and bispecific approaches aiming to build on zolbetuximab benchmark data.
Apr 13, 2026
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Apr 10, 2026
The CDC reported six new influenza-associated pediatric deaths in Week 6 of 2026, bringing the 2025-2026 U.S. season total to 71. About 90% of deaths with known vaccination status were in children not fully vaccinated.
Apr 08, 2026
NanoViricides has filed regulatory applications for its antiviral candidate NV-387, seeking both Rare Pediatric Disease Drug Designation for measles treatment and Orphan Drug Designation for both measles and MPox treatments. The company could qualify for significant incentives including tax credits, fee exemptions, market exclusivity, and potentially a Priority Review Voucher worth approximately $160 million. There are currently no approved drugs for treating either measles or MPox, with both diseases showing concerning case trends.
Apr 04, 2026
Trump administration cuts to U.S. science funding have raised fears of a brain drain, with thousands of grants cancelled and researchers moving abroad. Experts warned the losses could damage biomedical innovation and the economy.
Mar 14, 2026
Thousands of research positions have been terminated or frozen at federal agencies following deep cuts to U.S. science funding by the Trump administration, affecting work from aging studies to global food security.
Mar 14, 2026
GSK's RSV vaccine Arexvy received expanded FDA approval to cover all high-risk adults, adding approximately 21 million Americans under 50 to the eligible population and matching competitor approvals from Pfizer and Moderna.
